At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIB ProShares Ultra Nasdaq Biotechnology
Not Yet Opened 09-22 16:00:00 EDT
117.16
+3.69
+3.25%
盘后117.80
+0.64+0.54%
19:30 EDT
High118.15Low114.23Vol4.69K
Open115.67D1 Closing113.47Amplitude3.45%
Mkt Cap98.41MTradable Cap98.41MTotal Shares840.00K
T/O546.16KT/O Rate0.56%Tradable Shares840.00K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633
THOMSON REUTERS  ·  11:36
Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633
Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  04:34
Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day
Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales
Reuters  ·  04:17
Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales
Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Dow Jones  ·  00:47
Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Update: US Equity Indexes, Crude Oil Prices Mixed in Midday Trading
MT Newswires Live  ·  00:35
Update: US Equity Indexes, Crude Oil Prices Mixed in Midday Trading
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)
TIPRANKS  ·  09-22 23:20
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)
Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement
TradingKey  ·  09-22 23:15
Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement
Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi
TIPRANKS  ·  09-22 22:55
Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
TIPRANKS  ·  09-22 22:30
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
Maze jumps 25% to $27.99 after Vertex kidney disease data
TIPRANKS  ·  09-22 22:25
Maze jumps 25% to $27.99 after Vertex kidney disease data
Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal
Reuters  ·  09-22 21:48
Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal
Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial
Reuters  ·  09-22 21:45
Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial
Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial
THOMSON REUTERS  ·  09-22 21:36
Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial
Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease
Reuters  ·  09-22 21:04
Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease
Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria
Reuters  ·  09-22 21:02
Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria
Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease
THOMSON REUTERS  ·  09-22 21:00
Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease
Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity
THOMSON REUTERS  ·  09-22 21:00
Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity
Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026
THOMSON REUTERS  ·  09-22 21:00
Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026
Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial
MT Newswires Live  ·  09-22 20:50
Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study
TIPRANKS  ·  09-22 20:15
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

Introduction

Company Name.
ProShares Ultra Nasdaq Biotechnology
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Issue price:
--